Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

K-163-SZ Phase2 placebo-controlled study

Trial Profile

K-163-SZ Phase2 placebo-controlled study

Phase of Trial: Phase II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Pyridoxamine (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kowa
  • Most Recent Events

    • 22 Aug 2018 Planned End Date changed from 30 Nov 2018 to 30 Nov 2019.
    • 22 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top